NCT06745583 2026-06-03A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease PatientsElixiron Immunotherapeutics (Hong Kong) Ltd.Phase 2 Recruiting15 enrolled